Structure of macrophage migration inhibitory factor in complex with methotrexate

Area of Science:

• Biochemistry
• Pharmacology
• Drug Discovery

Background:

• Methotrexate (MTX) is a widely used drug for cancer and rheumatoid arthritis.
• Its primary mechanism involves inhibiting dihydrofolate reductase (DHFR), crucial for nucleotide synthesis and cell cycle progression.
• However, potential additional molecular targets remain an area of investigation.

Purpose of the Study:

• To investigate potential novel interactions of Methotrexate (MTX) beyond its known target, dihydrofolate reductase (DHFR).
• To elucidate the molecular basis of MTX interaction with macrophage migration inhibitory factor (MIF).
• To explore structure-based drug design opportunities for novel therapeutics targeting both MIF and DHFR.

Main Methods:

• Affinity-matrix technology was employed to identify potential binding partners of MTX.
• X-ray crystallography was utilized to determine the structural basis of the MTX-MIF interaction.
• Fragment molecular-orbital calculations were performed to quantify the interaction and identify key amino acid residues.

Main Results:

• The study identified a novel interaction between Methotrexate (MTX) and macrophage migration inhibitory factor (MIF).
• X-ray analysis provided the structural details of the MTX-MIF complex.
• Computational analysis pinpointed specific amino acids in MIF crucial for MTX binding.

Conclusions:

• Methotrexate (MTX) exhibits dual inhibitory potential, acting on both DHFR and MIF.
• The identified interaction provides a structural basis for understanding MTX's broader biological effects.
• This discovery opens avenues for designing novel small-molecule inhibitors with dual activity against MIF and DHFR for improved therapeutic outcomes.